Focus: Delcath is a specialty pharmaceutical company focused on developing innovative hepatic delivery systems and oncology treatments, with a public market presence trading under DCTH. The company operates at mid-cap scale (1,001–5,000 employees) from Queensbury, NY.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Delcath to get notified when they start hiring — the background below is worth knowing for when they do.
Help build intelligence for Delcath
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Delcath's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Recent NDA approval driving 18.5x revenue growth; company's sole marketed product with 9-year patent protection.
Delcath Systems to Host First Quarter 2026 Earnings Call - BioSpace
Delcath Systems to Host First Quarter 2026 Earnings Call BioSpace
European cancer guidelines add Delcath liver therapy for eye melanoma - Stock Titan
European cancer guidelines add Delcath liver therapy for eye melanoma Stock Titan
DELCATH SYSTEMS, INC. SEC 10-K Report - TradingView
DELCATH SYSTEMS, INC. SEC 10-K Report TradingView
Adjuvant Therapy for Advanced Melanoma - Medscape
Adjuvant Therapy for Advanced Melanoma Medscape
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo